by Rhoda Wilson, Expose News:
In September, a paper was published in the Journal of Orthomolecular Medicine which describes the scientific rationale for the hybrid orthomolecular protocol as well as providing detailed information on the protocol itself.
The hybrid orthomolecular protocol is a new strategy for treating cancer. It involves the use of various supplements and dietary interventions, including vitamin D, zinc, ivermectin, benzimidazoles and DON, as well as a ketogenic diet and fasting.
TRUTH LIVES on at https://sgtreport.tv/
One of the authors of the September paper was Canadian physician Dr. William Makis; another was Dr. Paul Marik, author of the book ‘Cancer Care: The Role of Repurposed Drugs and Metabolic Interventions in Treating Cancer’. Last week we published an introduction to Dr. Marik’s book, see HERE.
Announcing the paper for the new protocol for cancer had been published, Dr. William Makis tweeted the following:
First-in-the-world ivermectin, mebendazole and fenbendazole protocol in cancer has been peer-reviewed and published on 19 September 2024!
The future of cancer treatment starts NOW.
My thanks to lead authors Ilyes Baghli and Pierrick Martinez for their incredibly inspired work, FLCCC’s Dr. Paul Marik for his extensive work on repurposed drugs and every co-author who worked hard to bring this paper to life.
I hope that this peer-reviewed paper lays the groundwork for a brand-new future for cancer treatment.
Many of you know that I have been helping thousands of cancer patients with high-dose ivermectin, mebendazole and fenbendazole.
We are already starting to see incredible successes with these repurposed drugs.
Mainstream oncology collapsed after the rollout of contaminated covid-19 mRNA Vaccines.
Most oncologists abandoned their Hippocratic Oath, gave contaminated mRNA vaccines to all their cancer patients and took the mRNA jabs themselves.
Some oncologists have now developed mRNA-induced cardiac arrests, blood clots and turbo cancer. Others have already died suddenly.
These oncologists buried their heads in the sand and abandoned everything that it takes to be a good competent doctor.
However, there are doctors who are blazing a new path into the future. See you there!
Dr. William Makis on Twitter, 13 October 2024
The protocol for the prevention and treatment of cancer Dr. Makis was referring to was published in the Journal of Orthomolecular Medicine on 19 September 2024. Below is a summary of this paper; you can read the paper titled ‘Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol’ HERE.
Table of Contents
The Mitochondrial-Stem Cell Connection and Current Cancer Therapies
The concept of the mitochondrial-stem cell connection (“MSCC”) in cancer treatment combines the cancer stem cell theory and the metabolic theory, suggesting that cancer arises from impaired oxidative phosphorylation (OxPhos) in one or more stem cells, potentially leading to the formation of cancer stem cells (“CSCs”) and tumorigenesis, the gradual process by which normal cells acquire the ability to form tumours.
The MSCC theory aligns with the metabolic theory of cancer but specifically focuses on the crucial role of CSCs in every stage of the disease, differing from the CSCs theory, which typically presents cancer as a genetic disease.
Standard cancer therapies, based on the somatic mutation theory (“SMT”), target the DNA of cancer cells but do not restore OxPhos and sometimes even alter it, and only target bulk cells but cannot target CSCs, which have the strongest tumorigenic potential and are involved in metastasis.
Note: Metastasis is the process by which cancer cells break away from a primary tumour, travel through the bloodstream or lymphatic system, and establish new tumours in distant parts of the body.
The outcomes of new anti-cancer therapies have been limited, with an overall survival improvement of 2.4 months over the past fifteen years and 3.4 months over the past thirty years, which could be partially explained by the inability of these therapies to target the MSCC.
A hybrid orthomolecular protocol has been developed, which includes several orthomolecules, drugs and additional therapies that have demonstrated an ability to enhance OxPhos, reduce fermentable fuels, and target CSCs and metastasis, and is proposed as a new therapeutic strategy for cancer.
The key points that underpin the MSCC concept include: the alteration of OxPhos initiates tumorigenesis in one or more normal stem cells; the correlation between the degree of malignancy and significantly lower mitochondria and lower total respiratory capacity in tumour cells; and, cancer cells require glucose and glutamine as primary fuels to compensate for OxPhos insufficiency.
The tumour microenvironment, characterised by low pH, hypoxia, entropy, pressure and deformation, increased temperature, stroma, altered rotation of cytoplasmic water and damped bioelectricity or electromagnetic field, is a consequence of mitochondrial impairment.
Metastasis, the leading cause of cancer mortality, occurs due to fusion hybridisation between CSCs and macrophages, according to the MSCC.
The principles of the MSCC apply to all types of cancer, and the hybrid orthomolecular protocol has the potential to be a new therapeutic strategy for cancer treatment.
Vitamin C and Cancer Treatment
Vitamin C has been known for its anti-cancer properties for over 50 years, demonstrating cytotoxic effects on cancer cells both in vitro and in vivo.
